The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]‐mebendazole.
Open Access
- 1 September 1982
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 14 (3) , 453-455
- https://doi.org/10.1111/j.1365-2125.1982.tb02008.x
Abstract
Following the intravenous administration of a tracer dose (1.7 microgram) of [3H]-mebendazole to a man, an elimination half-life of 1.16 h was observed and the volume of distribution was calculated to be 2.03 l/kg. After oral administration of the same dose, an elimination half-life of 0.74 h was observed. The bioavailability of mebendazole from the solution was found to be 17%.Keywords
This publication has 7 references indexed in Scilit:
- Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid diseaseEuropean Journal of Clinical Pharmacology, 1982
- CHEMOTHERAPY OF ONCHOCERCIASIS: A CONTROLLED COMPARISON OF MEBENDAZOLE, LEVAMISOLE, AND DIETHYLCARBAMAZINEThe Lancet, 1981
- Plasma concentrations of mebendazole during treatment of echinococcosisEuropean Journal of Clinical Pharmacology, 1980
- Medical treatment for hydatids.1978
- MEDICAL TREATMENT FOR HYDATIDSThe Medical Journal of Australia, 1978
- Treatment of hepatic hydatid disease with mebedazole: preliminary results in four cases.BMJ, 1977
- Mebendazole in Enterobiasis Radiochemical and Pilot Clinical Study in 1,278 SubjectsJAMA, 1971